Posted by Michael Wonder on 20 Sep 2022
Aurinia announces European Commission approval of Lupkynis (voclosporin) for the treatment of lupus nephritis
19 September 2022 - Lupkynis is the first oral medicine approved in both the US and Europe for the treatment of adults living with active lupus nephritis.
Aurinia Pharmaceuticals announced that the European Commission has granted marketing authorisation of Lupkynis (voclosporin) to treat adults with active lupus nephritis, a serious complication of systemic lupus erythematosus.
